Abiraterone acetate (AA) is a standard of care for metastatic castration-resistant prostate cancer (CRPC). Despite a large food effect, AA was administered under fasting conditions in its pivotal trials. We sought to test the hypothesis that low-dose AA (LOW; 250 mg with a low-fat meal) would have comparable activity to standard AA (STD; 1,000 mg fasting) in patients with CRPC.
INTRODUCTION
Abiraterone acetate (AA) is a potent selective and irreversible inhibitor of CYP17, the primary enzyme complex responsible for the production of extragonadal (adrenal, intratumoral) androgens, including hormones dehydroepiandrosteronesulfate (DHEA-S), androstenedione, and others. 1 AA was approved by the Food and Drug Administration (FDA) in 2012 for metastatic castrationresistant prostate cancer (CRPC) on the basis of the results of a phase III randomized trial of AA (1,000 mg) plus prednisone (5 mg twice daily) versus placebo plus prednisone in chemotherapypretreated patients with CRPC, in which AA improved overall survival and progression-free survival (PFS) and mitigated the deterioration of quality of life in patients with metastatic CRPC.
2,3
More recently, AA has been demonstrated to improve survival when administered in conjunction with standard initial androgen deprivation therapy for metastatic castration-sensitive prostate cancer. 4, 5 AA is currently the most widely prescribed first-line medication for CRPC. 6 In 1 year, there were over 70,000 claims through Medicare Part D alone, 7 and according to the manufacturer, over 100,000 prescriptions for AA have been written in the first 5 years of availability, 8 at a wholesale acquisition cost of approximately $8,000 to $11,000 per month. 9, 10 Early clinical studies of AA demonstrated that when administered with food, drug exposure was significantly increased compared with fasting administration. 11, 12 According to the drug label, food leads to a five-to seven-fold increase in drug concentration with a low-fat meal and a 10-to 17-fold increase with a high-fat meal. 13, 14 Nevertheless, the registration studies of AA were conducted in the fasting state, resulting in the current approved dosage of 1,000 mg daily.
Given the potential pharmacoeconomic implication of lowering the dose of AA for the treatment of CRPC, we hypothesized that a lower dose taken with food would have an effect on CRPC similar to the approved dose taken fasting. We used serum prostate-specific antigen (PSA), a well-established disease biomarker, to measure anticancer activity. We also examined changes in extragonadal androgen production and AA plasma concentrations.
PATIENTS AND METHODS

Patient Selection
Eligible patients had a diagnosis of CRPC, defined as disease progression despite a testosterone level , 50 ng/dL (or surgical castration). Progressive disease was defined radiographically as either two or more new lesions on bone scan or soft tissue progression on computed tomography/ magnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors 1.1 15 or serologic progression with increasing PSA per standard guidelines. 16 Prior use of AA, enzalutamide, or other similar potent androgen pathway-targeted therapies was excluded. Prior use of chemotherapy and/or high-dose ketoconazole was allowed. Although high-dose ketoconazole has a similar mechanism of action to abiraterone, it does not preclude response to abiraterone and thus was allowed. 17 Other hormonal therapies, any herbal product known to decrease PSA levels, and any systemic corticosteroid (other than prednisone # 10 mg daily) were not allowed. Eligibility also included an Eastern Cooperative Oncology Group performance status # 2, acceptable renal and hepatic function, and adequate baseline blood pressure and electrolytes.
Study Design and End Points
This was a multinational randomized open-label study conducted at six sites in two countries, the United States and Singapore. Enrolled participants were randomly assigned in a one-to-one ratio to receive AA 1,000 mg fasting (STD) or 250 mg with a low-fat meal (LOW). The only stratification factor was prior history of high-dose ketoconazole treatment of CRPC. Treatment was administered on an outpatient basis continuously. The commercially available drug was procured by patients through their pharmacy. For patients in the STD arm, AA 1,000 mg was taken first thing in the morning after an overnight fast of at least 8 hours and at least 2 hours before any food intake, per the prescribing information. For the LOW arm, AA 250 mg per day was taken either concomitantly or within 30 minutes of a conventional low-fat breakfast. The nature of the breakfast was at the discretion of the patient; however, patients were told to avoid consumption of high-fat items (eg, sausage, bacon, deep-fried foods, etc) with AA. Food diaries completed by study participants were reviewed by study personnel for adherence. All patients received prednisone at a dose of 5 mg orally twice daily and kept both food and drug dosing diaries, which were reviewed by research staff for compliance.
The review boards at all participating institutions approved the study, which was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines of the International Conference on Harmonization. All patients signed a written informed consent before the conduct of any study procedures and after a full explanation of the study to the patient by the study investigator.
The primary objective of the study was to compare the antitumor activity of LOW AA with the STD AA dose, as assessed by change in serum PSA. Although not a clinically validated surrogate end point, PSA is an androgen receptor-regulated gene, and changes in PSA have been correlated with overall survival on abiraterone.
18 Secondary objectives were to compare AA pharmacokinetics between the arms, PSA response rate ($ 50% reduction in PSA after 12 weeks of therapy), and PFS; to compare the safety profile of LOW with STD; and to evaluate the pharmacodynamic effect of LOW as assessed by reduction in the androgens testosterone and DHEA-S.
Study Procedures
Visits occurred weekly for the first 2 weeks, at week 4, and then monthly. PSA, standard chemistries, and blood counts were assessed monthly by local laboratories and reported centrally. The clinical-grade laboratory accreditation served to ensure assay constancy and sensitivity of PSA measurements. Disease burden assessed with standard nuclear medicine bone scan and abdomen/pelvis cross-sectional imaging was conducted every 12 weeks in accordance with the standard working group guidelines.
16 Serum testosterone (high throughput liquid chromatography) and DHEA-S (chemi-immunoassay) were also assessed locally within a clinical-grade laboratory every 12 weeks.
Plasma was collected for drug pharmacokinetic (abiraterone and metabolite) analysis after 8 days of therapy (before and 2, 3, and 4 hours after dosing) and monthly for the first 4 months (2 hours after dosing). The 2-hour time point was selected for collection because it is the time of maximum concentration after dosing for AA in prior studies.
14 These analyses were conducted within the National Cancer Institute Pharmacology Laboratory using liquid chromatography-mass spectrometry with electrospray ionization, as detailed in the Data Supplement.
Statistical Analysis
Randomization was stratified by prior ketoconazole use and was accomplished using the method of permuted blocks and the random number generator in Stata software (Stata, College Station, TX). Block sizes were varied and known only to the study statistician. The primary end point of the study was change in PSA from baseline to 12 weeks. The benchmark data for our power calculations were adapted from the phase II trial by Danila et al 19 and the much larger, randomized phase III trial in the postdocetaxel CRPC setting conducted by de Bono et al, 2 which used the standard, high-dose fasting regimen. Pooling these data (weighted by sample size) yielded a historical PSA response rate (reduction in PSA by $ 50%) of 30%. This study used a noninferiority trial design, with analysis of PSA change as a continuous variable 20 (transformed to the log scale). Additional details are provided in the Data Supplement. A total sample size of 72 patients (36 per treatment arm) provided 80% power for the noninferiority test, using a one-sided alpha level of .10.
The Kaplan-Meier 21 approach was used to estimate PFS rates, and the stratified log-rank test was performed to compare PFS between the two treatment arms, adjusting on the stratification factor. PSA and radiographic progression were defined according to Working Group criteria.
16
Patient progression for the PFS end point was defined as either PSA or radiographic progression, whichever occurred first. For patients without disease progression at the time of analysis, PFS was censored at the time of the patient's last available tumor assessment.
The drug and hormone concentrations were analyzed at the time points outlined previously. Group comparisons were performed using twosample t tests or nonparametric, Wilcoxon rank sum tests. Correlation between trough concentration and PSA change was summarized by the Spearman correlation coefficient, and intrapatient and interpatient pharmacokinetic variability was assessed by analysis of variance.
RESULTS
Patients and Treatments
Between January 2012 and March 2016, 72 patients with CRPC were enrolled and underwent randomization, with 36 patients randomly assigned to each treatment arm. Four patients withdrew consent before initiating therapy (two in each arm) and were not followed. Thus, 34 patients per arm were treated per protocol (Fig 1) . Patient characteristics were well balanced between the two groups, representing a typical CRPC population, with the majority of patients in this study receiving AA in the predocetaxel setting ( Table 1 ). The only apparent difference between arms was that the LOW arm had a higher percentage of patients who selfidentified as African American (31% v 14% in the STD group).
Efficacy
Subsequent to treatment with AA, the magnitude of reduction in PSA from baseline to 12 weeks was actually greater in the lowdose group, that is, the mean log change was 21.59 in LOW versus 21.19 in STD (with a pooled standard deviation of 1.62). The upper one-sided 90% confidence limit for the difference between the two arms (LOW 2 STD) was 0.11 (standard deviation, 0.068). Thus, according to the predefined criteria (Appendix, online only), noninferiority of LOW was established. It should be noted that the translation of PSA response rates to differences on the continuous log PSA scale is highly dependent on the assumption of normality of the distribution of log PSA changes. Normal probability plots (Appendix Figs A1B and A1C, online only) indicate that the normality assumption is reasonably well satisfied here.
PSA changes while receiving treatment were consistent with prior studies.
2,3 At 12 weeks, there were only three of 34 evaluable patients (9%) with primary PSA progression (post-treatment PSA increase as best response) within the STD group. Similarly, in the LOW group, one patient (3%) had primary PSA progression. The majority of patients experienced a decrease in PSA at 12 weeks in both arms (Fig 2A) . Not only were the PSA changes similar on a continuous log scale, there was a similar absolute PSA response rate (as a dichotomous variable) at 12 weeks in both arms: 50% in the STD arm and 58% in the LOW arm. The lower one-sided 90% confidence limit for the difference between the two arms in PSA response rates (LOW 2 STD) was 27%. Therefore, we can assert with 90% confidence that the LOW arm is at most 7% worse than STD. PSA change from baseline to nadir for both groups was also assessed (Fig 2B) . The nadir PSA response rate was 61% in the STD group and 69% in the LOW group (lower, one-sided 90% confidence limit of 26%). For reference, the PSA response rate was 62% in the landmark prechemotherapy phase III abiraterone study.
3 Notably, not only was PSA response similar between arms, but duration of response was also comparable, with a median PFS of 8.6 months in both arms (P = .38; Fig 3) . Because only four patients per arm received prior ketoconazole, no additional analysis was undertaken for the efficacy end points on the basis of the stratification factor.
Pharmacokinetics
Average abiraterone trough concentrations were significantly higher in the STD arm compared with the LOW arm (t test log trough concentration P , .001; Fig 4A) . Interestingly, despite jco.org previous literature suggesting similar maximum concentration (C max ) between 250 mg with food compared with 1,000 mg fasting (approximately 500 nM), 11 we found that the C max was also higher in the STD arm compared with the LOW arm (t test log C max P = .012; Data Supplement). However, interindividual variability was higher in the STD arm (coefficient of variation, 151% v 106%; P , .001). Similar results were observed when the 2-hour sample was analyzed (Appendix Fig 2B) .
An association between plasma trough concentration and PSA response to AA has been previously reported. 22 However, within our data set, there was no evidence of a clinically significant correlation between the trough concentration and change in PSA (Spearman correlation coefficient, 20.12; P = .37; Fig 4B) . There was also no statistically significant association between PSA response (50% reduction in PSA) regardless of arm and trough concentration (t test P = .11; Appendix Fig 2C, online only) . In sum, although there were higher drug concentrations in the STD arm compared with the LOW arm, there was higher pharmacokinetic variability and no clear association within this study between drug concentration and efficacy.
Endocrine Pharmacodynamic Effects
A hallmark of AA on-target efficacy is change in androgen levels. We therefore sought to assess the association of dose with this important endocrine biomarker. Baseline circulating testosterone levels were in the castrate range in both treatment groups (Table 1 ). Subsequent to AA administration, overall testosterone levels fell in both arms to a similar extent, although the magnitude of this decrease was not able to be determined with accuracy because of the sensitivity of the commercial assay. DHEA-S is the most abundant extragonadal serum androgen in this patient population; its levels predictably fall after abiraterone administration and mirror the decline of the other androgens testosterone and androstenedione. 17, 23 With this background and because its standard of care measurement uses a highly sensitive assay with a dynamic range at low levels, DHEA-S was measured serially in this study. Like testosterone, baseline levels of DHEA-S are prognostic in an abiraterone-treated population.
23 Baseline DHEA-S levels were similar in both arms (Table 1 ) and declined robustly with AA in the LOW arm, to 10.2 (5.9) mg/dL at cycle 4 and to 8.9 (6.1) mg/dL at the end of the study time point. This decrease in DHEA-S mirrored the levels seen with STD, which were 13.3 (6.4) mg/dL and 9.1 (6.2) mg/dL at cycle 4 and at the end of the study, respectively (Fig 5) . Therefore, despite higher drug concentrations in the STD arm, the LOW arm showed equivalent activity with respect to endocrine effects, in addition to the associated change in PSA metrics.
Safety
Overall, the adverse events were consistent with prior studies of AA, with all adverse events, regardless of attribution, observed in at least 15% of patients in either arm listed in Table 2 . Adverse events of special interest, as defined in the phase III studies 2,3 were similar in both arms (Table 2) . Although there were numerically more patients with grade 3 or higher events in the LOW arm, this was not statistically significant (32.4% v 17.6%; P = .26). There were two lethal adverse events, both in the STD arm (sepsis and small intestinal obstruction); neither was attributed to AA. Time (months) 
DISCUSSION
This prospective randomized study comparing low-dose AA with food with standard dose fasting suggests noninferiority of a 75% dose reduction of AA, if given in the prandial state. Importantly, both PSA response and time to progression in both arms within this study were comparable to previous studies. 3, 11, 24 In further support of the central hypothesis, serum androgen levels decreased to a similar extent within both arms in the study. Although the sensitivity of the testosterone assay used was not sufficient to measure testosterone changes at the lowest measured levels, DHEA-S, which has been used in measuring abiraterone efficacy, 17,23 was able to be measured with high sensitivity (because of the relative abundance of this androgen in circulation) and fell to the same extent in both arms of the study. Thus, the two pharmacodynamic end points examined, changes in PSA and androgen levels, point to similarity between LOW and STD dosing of AA for patients with CRPC.
Notably, despite prior studies and the FDA label citing a large food effect on bioavailability, the pharmacokinetic analyses within this larger randomized study suggest that the food effect on AA absorption and bioavailability may not be as robust as previously reported. Within all pharmacokinetic time points analyzed, STD dosing resulted in higher drug levels. This is somewhat consistent with a recently reported study that found that the C max increased only 150% to 200% with food, even with a high-fat meal. 25 Furthermore, the less robust food effect observed in this study may have been due to a more fat-restrictive low-fat diet compared with standard low-and high-fat diets used in FDA-directed food-effect studies. It has been argued that patients with cancer cannot be routinely relied on to follow dietary instructions with respect to oral medications, which could lead to high exposure variability in the fed state despite a constant dose. 26 In contrast, our study demonstrated a statistically higher variability in pharmacokinetics within the standard fasting arm. This improved pharmacokinetic variability with food is consistent across orally bioavailable oncology medications when taken in the prandial state that maximizes bioavailability. 27 Although there were no discrepancies in patient drug diaries, the composition and timing of food intake after AA may have contributed to the high observed variability. 28 Importantly, our study found no significant correlation between steady-state (trough) abiraterone concentration and PSA response, although the three patients with the highest drug concentrations experienced robust PSA responses. These three patients with abiraterone levels approximately triple the median heavily contributed to the higher variability in the STD arm and the higher abiraterone concentration in general within this arm compared with the LOW arm. Given the equivalence between the arms on PSA response and adrenal androgen synthesis, our study suggests that LOW dosing achieves pharmacologically sufficient AA exposure and raises the possibility that a lower dose of AA, even in the fasted state, may be sufficient. Within oncology, there continues to be a focus on equating the optimal dose with the maximally 
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End Point jco.org tolerated dose, a paradigm not well justified in an era of targeted therapy.
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Although designed to demonstrate noninferiority, this study lacks the power to rule out a smaller difference between the two dosing arms than a predefined noninferiority margin of 15%. Our data yield a lower 90% confidence limit for the absolute difference in PSA response rates (LOW 2 STD) of 27%; therefore a smaller 10% noninferiority margin would also have been supported. However, with a more conservative one-sided 95% confidence limit, the lower bound between the difference in PSA response rates in our study is 211%.
In addition, because the study did not mandate that patients stay in the study past PSA progression, nor did it collect radiographic progression past PSA progression, we were unable to capture fully validated CRPC end points of radiographic PFS and overall survival. 30 However, prior larger studies in metastatic prostate cancer have shown an association between PSA progression, according to standard criteria, and overall survival. 31 Thus, although not powered for a practice-changing clinically validated end point, the equivalence in PSA PFS between the two arms is provocative, and additional studies should be undertaken.
There are several other dosing strategies that could be studied on the basis of the results of this study. Given the prolonged effect on androgen synthesis after a single dose of AA, 32 500 mg every other day with food or even every fourth day could be tested. Because lower drug concentrations than we predicted were seen with LOW, 250-mg dosing (or 500 mg intermittently) could also be explored using a high-fat meal.
The pharmacoeconomic implications of this study's findings are compelling. AA has an approximate retail cost of $10,000 per month. With a median time receiving treatment of 16.5 months in metastatic CRPC, 3 the per-patient cost savings with the LOW dosing would exceed $100,000. Furthermore, AA was recently shown to improve survival in the metastatic castration-sensitive prostate cancer setting, with median PFS estimates of 33 to 44 months, potentially resulting in per-patient cost savings of more than $300,000. 4, 5 Given the prevalent paradigm of developing drugs with large food effects under fasting conditions, there are multiple other opportunities to lower drug costs by administration with food.
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